Novo Nordisk to present data from STEP UP trial on a higher dose of Wegovy® (semaglutide 7.2 mg) for those in need of greater weight loss Data will expand semaglutide evidence in both a clinical and ...

Analysis of a large unsubsidized digital weight-loss service reveals that consistent treatment adherence and active ...

CHICAGO -- Adding investigational cagrilintide to a GLP-1 receptor agonist increased weight loss in adults with obesity with or without type 2 diabetes, a pair of phase IIIa trials found. This ...

The European Association for the Study of Obesity now recommends the 2 treatments for obesity and most associated complications. According to an EASO news release, these new recommendations reflect ...

Semaglutide or tirzepatide should be first-line drugs for obesity and most of its related complications, new guidance from the European Association for the Study of Obesity recommended. The authors of ...

Oral semaglutide at a dose of 25 mg may provide an alternative treatment option to injectable semaglutide (2.4 mg) and higher-dose oral semaglutide (50 mg) for persons with overweight or obesity. In a ...

Results from the Phase 3b STEP UP trial showed that a higher dose of semaglutide (7.2 mg) delivered 21%* weight loss in people with obesity with a third of participants losing 25% or more of their ...

Nutritional guidance to support safe weight loss is frequently lacking for adults with obesity or type 2 diabetes receiving semaglutide or tirzepatide.

CHICAGO -- Semaglutide (Ozempic) reduced glucose levels and weight among patients with type 1 diabetes and obesity, a randomized trial showed. In this 26-week, double-blind trial of 72 adults, 36% who ...

Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 ...